Ibogaine for Opioid Addiction
The most effective single-session intervention for opioid dependence
Evidence-based treatment for heroin, fentanyl, oxycodone, hydrocodone, morphine, codeine, and tramadol addiction. Ibogaine resets opioid receptors, eliminates withdrawal within hours, and repairs neural pathways damaged by chronic opioid use.
The Opioid Crisis: Why We Need a Better Approach
The opioid epidemic has claimed more American lives than every war since Vietnam combined. Conventional treatments, while valuable, are failing the majority of patients. The numbers demand a fundamentally different approach.
107,000+
Annual opioid overdose deaths in the United States (CDC 2023)
80%
Relapse rate within first year of conventional treatment (NIDA)
$78.5B
Annual economic burden of opioid misuse in the U.S. (CDC)
21-29%
Of patients prescribed opioids for chronic pain who misuse them
Why Traditional Treatments Have High Relapse Rates
Medication-Assisted Treatment (MAT)
- Methadone and buprenorphine (Suboxone) replace one opioid with another
- Require daily dosing for months to years, often indefinitely
- Do not address the underlying neural damage that drives addiction
- Withdrawal from MAT itself can be prolonged and severe
- Stigma around MAT prevents many patients from seeking help
Behavioral Rehabilitation
- 30-day programs are insufficient for the depth of neurological damage
- Patients endure brutal withdrawal during detox, increasing dropout
- Cravings persist for months after physical withdrawal ends (PAWS)
- Psychological approaches cannot repair receptor damage alone
- Cost ($30,000-$60,000+ per stay) creates access barriers
The core problem:Conventional treatment manages symptoms of addiction without repairing the neurological systems that create and sustain dependence. Ibogaine is the only known substance that addresses opioid addiction at the receptor level, the neural growth factor level, and the psychological level simultaneously—in a single treatment session.
How Ibogaine Treats Opioid Addiction
Ibogaine’s multi-receptor pharmacology makes it uniquely effective against opioid dependence. No other known substance simultaneously resets opioid receptors, eliminates withdrawal, promotes neuronal repair, and facilitates deep psychological processing.
Opioid Receptor Reset (Mu, Delta, Kappa)
Ibogaine interacts with all three opioid receptor subtypes, restoring them to pre-addiction baseline sensitivity. The mu-opioid receptor — the primary target of heroin, fentanyl, and prescription painkillers — is reset from its downregulated, tolerance-driven state. Delta and kappa receptor modulation further normalizes the brain's endogenous opioid system, restoring natural pain regulation and emotional processing.
This receptor reset is why patients wake up the morning after treatment without withdrawal — the brain no longer 'needs' external opioids to function normally.
Withdrawal Elimination (80-90% Within Hours)
Within 4-8 hours of administration, ibogaine eliminates the vast majority of acute opioid withdrawal symptoms. Muscle aches, restless legs, nausea, vomiting, cold sweats, insomnia, anxiety, and gastrointestinal distress are resolved — not suppressed, but resolved — as the receptor reset takes effect. Most patients report waking the next morning feeling physically normal for the first time in months or years.
Conventional detox requires 7-14 days of severe suffering. Ibogaine accomplishes what cold-turkey withdrawal takes weeks to achieve, but without the agony.
GDNF Upregulation: Neural Pathway Repair
Ibogaine stimulates production of Glial Cell Line-Derived Neurotrophic Factor (GDNF) — a protein critical for the survival and regeneration of dopaminergic neurons. Chronic opioid use degrades the brain's dopamine circuitry, leaving patients unable to experience natural pleasure or motivation (anhedonia). GDNF reverses this damage by promoting neuronal growth, restoring dendritic branching, and rebuilding the reward pathways that addiction has eroded.
GDNF upregulation is why ibogaine's benefits are not just immediate but progressive — neural repair continues for weeks to months after the treatment session.
NMDA Receptor Antagonism: Breaking Addiction Patterns
As a non-competitive NMDA receptor antagonist, ibogaine disrupts the glutamate-driven learning pathways that encode addictive behaviors. Opioid addiction creates powerful conditioned associations — places, people, emotions, and sensory cues become hardwired triggers for drug-seeking behavior. NMDA antagonism interrupts these associative memories, weakening the automatic behavioral loops that drive compulsive use and relapse.
This mechanism is shared with ketamine, but ibogaine's effects are far more sustained due to its metabolite noribogaine, which continues NMDA modulation for days.
Serotonin Transporter Effects: Addressing Underlying Depression
Many opioid-dependent patients self-medicate for underlying depression and emotional pain. Ibogaine modulates the serotonin transporter (SERT), producing antidepressant effects that address the root psychological conditions that often initiated opioid use. Unlike SSRIs that require weeks to take effect and daily dosing, ibogaine's serotonergic action is immediate and sustained through its metabolite noribogaine.
This dual action — treating both the addiction and the co-occurring depression — is critical for preventing relapse driven by untreated mental health conditions.
Noribogaine: Sustained Anti-Addictive Protection
Ibogaine is metabolized in the liver into noribogaine, a long-acting metabolite that remains active in the body for weeks to months after treatment. Noribogaine continues to modulate opioid, serotonin, and NMDA receptors during the critical early recovery period, providing sustained craving suppression and emotional stability. This extended protective window gives patients time to build new habits, engage in therapy, and establish the foundations of lasting recovery.
Noribogaine's 24-48 hour half-life and gradual tissue release mean its effects extend far beyond the acute treatment session — a built-in relapse prevention mechanism.
Why No Other Treatment Does What Ibogaine Does
Methadone and buprenorphine activate the same mu-opioid receptors that heroin and fentanyl target — they replace one opioid with another. Naltrexone blocks opioid receptors but does nothing to repair the neural damage. Clonidine manages some withdrawal symptoms but does not address cravings or receptor reset. Ibogaine is the only known substance that simultaneously resets all three opioid receptor subtypes, eliminates withdrawal, upregulates GDNF for neural repair, blocks NMDA-encoded addiction patterns, provides antidepressant effects through serotonin modulation, and generates a long-acting metabolite that sustains these benefits for weeks. This is why ibogaine can accomplish in a single session what conventional treatment attempts over months or years — and why its outcomes consistently outperform all other available interventions for opioid dependence.
Evidence-Based Treatment Approach: Total Alkaloid Extract
The majority of ibogaine clinics worldwide use ibogaine hydrochloride (HCL) — a purified, isolated form of a single alkaloid from the Tabernanthe iboga plant. While effective, HCL-only treatment misses a critical dimension of the medicine.
A small number of leading providers use Total Alkaloid (TA) extract derived directly from genuine Tabernanthe iboga root bark — containing all 12+ naturally occurring alkaloids. Unlike ibogaine HCL used by most clinics (semi-synthesized from Voacanga africana, a different African plant, containing only 1 isolated alkaloid), TA extract preserves the full alkaloid spectrum for a synergistic therapeutic effect that single-compound HCL cannot replicate. Learn about TA vs HCL →
Why Total Alkaloid Extract Matters
- Ibogaine is only one of the active alkaloids. Ibogamine, tabernanthine, coronaridine, voacangine, and other co-occurring compounds each contribute unique pharmacological effects that enhance the overall treatment
- TA extract produces a more balanced, gradual onset and offset compared to the sharp peak of pure HCL — reducing cardiac stress and improving patient comfort
- The synergistic interaction between multiple alkaloids appears to produce deeper psychological processing and more thorough receptor modulation
- Clinical observation over thousands of treatments suggests TA extract yields better long-term outcomes for opioid addiction than HCL alone
- The natural alkaloid profile mirrors the traditional Bwiti ceremonial preparation, which has been used safely for centuries in West Africa
Full-Spectrum Medical Protocol
- Extract Type
- Total Alkaloid (TA) — full-spectrum iboga
- Screening
- 12-lead ECG, comprehensive blood panel, liver and kidney function, psychological evaluation
- Monitoring
- Continuous cardiac telemetry, pulse oximetry, blood pressure, and nursing care throughout treatment
- Medical Staff
- On-site physician, registered nurses, emergency protocols and equipment
- Location
- Cozumel, Mexico — purpose-built medical facility
- Integration
- Pre- and post-treatment psychological support, aftercare planning
HCL vs. Total Alkaloid: The Key Difference
Think of ibogaine HCL as a single instrument playing a melody. Total Alkaloid extract is the full orchestra. Each alkaloid contributes a distinct pharmacological voice, and together they produce a therapeutic effect that is richer, more nuanced, and clinically more effective than any single compound in isolation. A small number of clinics worldwide offer this full-spectrum approach.
Opioids Treated with Ibogaine
Ibogaine effectively treats dependence on all classes of opioids. Each substance presents unique clinical considerations that experienced providers account for in their treatment protocols.
Fentanyl
Duragesic, Actiq, Sublimaze, illicit pressed pills
Relative Potency
50-100x morphine
Treatment Challenge
Extreme receptor binding, fat-soluble (prolonged tissue release), rapid tolerance escalation, extended withdrawal (7-14+ days)
Ibogaine Response
Requires modified protocols: higher doses or extended booster sessions over 2-3 days. Pre-treatment stabilization may include a brief buprenorphine bridge. Experienced clinics have developed fentanyl-specific protocols.
Heroin
Diamorphine, diacetylmorphine (street names vary)
Relative Potency
2-3x morphine
Treatment Challenge
Rapid onset creates powerful psychological dependence, IV use adds behavioral compulsivity, street supply often contains fentanyl
Ibogaine Response
Ibogaine's original and most-studied application. Excellent response rates: 80-90% withdrawal elimination, 50-65% long-term abstinence with proper aftercare.
Oxycodone
OxyContin, Percocet, Roxicodone, Endone
Relative Potency
1.5x morphine
Treatment Challenge
High abuse potential from time-release formulations, smooth pharmacokinetic profile creates insidious dependence, often gateway to heroin or fentanyl
Ibogaine Response
Standard ibogaine protocols are highly effective. Patients typically experience complete withdrawal resolution and significant craving reduction within 24 hours.
Hydrocodone
Vicodin, Norco, Lortab, Zohydro
Relative Potency
0.6x morphine
Treatment Challenge
Most commonly prescribed opioid in the U.S., frequently escalates from legitimate prescriptions, combination with acetaminophen adds liver toxicity risk
Ibogaine Response
Excellent response to standard protocols. Lower receptor binding affinity means ibogaine achieves thorough receptor reset with standard dosing.
Morphine
MS Contin, Kadian, Avinza
Relative Potency
Reference standard (1x)
Treatment Challenge
Long medical use creates deep physical dependence, chronic pain patients face dual challenge of addiction and pain management
Ibogaine Response
Well-studied response. Ibogaine resets morphine-adapted receptors effectively, and its own analgesic properties help manage the transition for chronic pain patients.
Codeine
Tylenol 3, Codeine Contin, various cough syrups
Relative Potency
0.15x morphine
Treatment Challenge
Lower potency often masks severity of dependence, patients underestimate their addiction until escalation occurs
Ibogaine Response
Lower ibogaine doses typically sufficient. Codeine dependence responds quickly and thoroughly to treatment.
Tramadol
Ultram, ConZip, Ultracet
Relative Potency
0.1x morphine (plus SNRI activity)
Treatment Challenge
Unique dual mechanism: opioid receptor agonism plus serotonin-norepinephrine reuptake inhibition. Discontinuation involves both opioid withdrawal AND antidepressant discontinuation
Ibogaine Response
Requires careful protocol due to tramadol's serotonergic activity. Adequate washout period critical to avoid serotonin syndrome. Experienced clinics have developed specific tramadol protocols.
Also effective for MAT medications:Ibogaine can treat dependence on methadone and buprenorphine (Suboxone/Subutex) themselves. Many patients come to ibogaine treatment after years on maintenance therapy, seeking genuine freedom from all opioid dependence. These cases require modified protocols due to the long half-lives of methadone and buprenorphine. See our detailed comparisons:Ibogaine vs. MethadoneandIbogaine vs. Suboxone.
Ibogaine vs. Conventional Opioid Treatment
A direct comparison of treatment approaches for opioid dependence.
| Factor | Methadone / Suboxone | Behavioral Rehab | Cold Turkey / Detox | Ibogaine |
|---|---|---|---|---|
| Withdrawal experience | Suppressed but not eliminated; MAT withdrawal is its own challenge | Managed with comfort meds; still 5-14 days of significant suffering | Full severity; 7-14 days of intense physical and psychological agony | 80-90% eliminated within hours of treatment |
| Treatment duration | Months to years of daily dosing; often indefinite | 28-90 days inpatient; outpatient varies | 5-14 days acute; months of PAWS | Single session (24-36 hours); effects last months |
| Receptor repair | No — occupies the same receptors opioids target | Slow natural recovery over months; often incomplete | Slow natural recovery; 6-18 months for baseline | Active reset of mu, delta, and kappa receptors |
| Neural regeneration | None | None directly (exercise may help) | None | GDNF upregulation promotes neuronal repair |
| Craving reduction | Partially suppressed while on medication | Modest; psychological strategies only | Minimal; cravings often intensify | 70-80% significant reduction; sustained by noribogaine |
| Psychological healing | None from medication; therapy separate | Talk therapy and group work; effectiveness varies | None | Deep introspective experience processes underlying trauma |
| 12-month abstinence rate | 30-50% (while still on medication) | 10-20% after completing program | 5-10% | 50-65% (with aftercare integration; Noller et al., 2018) |
| Ongoing medication needed | Yes — daily dosing required | Varies; many relapse without support | No medication; high relapse risk | No — single treatment; optional boosters |
This comparison is for educational purposes. MAT saves lives and is appropriate for many patients. Treatment decisions should be made with qualified medical professionals based on individual circumstances.
The Treatment Process: What to Expect
Ibogaine treatment for opioid addiction is a structured medical process with distinct phases. Understanding each phase helps patients prepare mentally and physically for what lies ahead.
Pre-Screening and Medical Evaluation
Comprehensive medical screening begins remotely. 12-lead ECG to evaluate cardiac health (QTc interval must be within safe range). Complete blood panel including liver function (ALT, AST, bilirubin), kidney function (creatinine, BUN, GFR), electrolytes (potassium, magnesium, calcium), and metabolic panel. Full medication and substance use history. Patients on methadone, buprenorphine, or long-acting opioids may need to transition to short-acting opioids before treatment. Patients on SSRIs, SNRIs, or other serotonergic medications require supervised tapering and washout.
Stabilization Period
Patients arrive at the treatment facility and enter a stabilization phase. Final medical assessments are completed on-site. For fentanyl patients, this may include transitioning off street fentanyl (which has unpredictable potency) onto short-acting pharmaceutical opioids for controlled titration. Hydration, nutrition, and rest are prioritized. The clinical team establishes baseline vitals and the patient meets with a therapist to set treatment intentions and prepare psychologically for the experience.
The Flood Dose (Ibogaine Session)
The therapeutic (flood) dose of ibogaine is administered under continuous medical supervision with cardiac monitoring via telemetry. The experience unfolds in stages: onset phase (1-2 hours) as ibogaine takes effect; visionary phase (4-8 hours) with vivid, often autobiographical visions; introspective phase (8-20 hours) of deep reflection and emotional processing; and resolution phase (gradual return to baseline). Throughout, the medical team monitors cardiac rhythm, blood pressure, oxygen saturation, and overall patient stability. For opioid patients, withdrawal symptoms diminish progressively during the first 4-8 hours.
Acute Recovery and Integration
Rest, rehydration, and nutritional support. Daily integration sessions with a therapist to process insights from the ibogaine experience and begin translating them into actionable life changes. Noribogaine is actively metabolizing during this period, providing ongoing craving suppression and emotional stability. Physical assessment confirms withdrawal resolution. Sleep patterns begin normalizing. Patients typically describe feeling 'clear' — as if a neurological fog has lifted.
Aftercare and Long-Term Integration
The noribogaine window creates an extended period of reduced cravings and enhanced neuroplasticity — a critical opportunity for behavioral change. Recommended aftercare includes ongoing therapy (individual and/or group), lifestyle restructuring (exercise, nutrition, sleep hygiene, stress management), community support (12-step, SMART Recovery, or peer groups), and relapse prevention planning. Some patients benefit from a booster session at 3-6 months. Long-term success correlates strongly with the quality and consistency of aftercare engagement.
Clinical Evidence and Outcomes
Decades of clinical observation and a growing body of published research support ibogaine’s efficacy for opioid dependence.
Published Research
Brown & Alper (2017)
Observational study of 88 opioid-dependent individuals treated with ibogaine in New Zealand. 80% reported elimination or significant reduction of withdrawal symptoms within 24 hours. 50% maintained complete abstinence at 12 months.
Noller, Frampton & Yazar-Klosinski (2018)
Observational study of 14 opioid-dependent participants in New Zealand. Statistically significant reductions in Subjective Opioid Withdrawal Scale (SOWS) scores at one month follow-up. No serious adverse events with proper medical screening.
Mash et al. (2018)
Phase I/II clinical trials at the University of Miami demonstrating safety and efficacy of ibogaine for opioid detoxification. Established cardiac safety parameters including QTc monitoring protocols now standard in clinical practice.
Davis, Barsuglia et al. (2017)
Survey of 88 individuals who self-administered ibogaine for opioid dependence. 80% reported cessation of opioid use following treatment. Significant reductions in withdrawal severity and craving intensity.
Schenberg et al. (2014)
Systematic review of ibogaine-treated patients in Brazil. 75% of opioid-dependent patients achieved sustained abstinence or dramatically reduced use at long-term follow-up.
Outcome Summary
Acute Withdrawal Elimination
80-90%
Within 4-8 hours of ibogaine administration
Craving Reduction
70-80%
Significant or complete reduction, sustained by noribogaine
12-Month Abstinence
50-65%
With proper aftercare — Noller et al., 2018 (vs. 10-20% conventional treatment)
PAWS Reduction
Significant
Post-acute withdrawal symptoms reduced or eliminated via GDNF and receptor reset
Patient Experiences
“Fifteen years on oxycodone after a back surgery. Three rehabs, two methadone programs, one Suboxone attempt. I was ready to give up. After ibogaine, I woke up the next day without withdrawal for the first time in over a decade. It has been fourteen months. I am still free.”
— 48-year-old male, oxycodone dependence, 14 months opioid-free
“I was doing 2 grams of heroin a day plus whatever fentanyl was in it. My family had planned my funeral. Ibogaine did not just stop the withdrawal — it showed me why I was using. For the first time, I understood the pain I was running from. That understanding changed everything.”
— 31-year-old female, heroin/fentanyl dependence, 11 months opioid-free
Individual results vary. These accounts are representative of reported patient experiences. Consult qualified medical professionals before pursuing treatment.
Critical: SSRI & Medication Safety
Many opioid-dependent patients are also taking antidepressants, anti-anxiety medications, or other psychiatric medications. Some of these create dangerous, potentially fatal interactions with ibogaine that must be addressed before treatment can proceed safely.
Serotonin Syndrome Risk
Ibogaine has significant serotonergic activity. Combining it with SSRIs (fluoxetine, sertraline, escitalopram, paroxetine, citalopram), SNRIs (venlafaxine, duloxetine), MAOIs, or other serotonergic medications can causeserotonin syndrome — a potentially life-threatening condition characterized by hyperthermia, muscle rigidity, autonomic instability, and altered mental status. All serotonergic medications must be tapered and washed out under medical supervision before ibogaine treatment.
CYP2D6 Enzyme Interactions
Ibogaine is metabolized primarily by the CYP2D6 liver enzyme. Several common medications — including fluoxetine (Prozac), paroxetine (Paxil), bupropion (Wellbutrin), and certain antihistamines — inhibit CYP2D6, which can dramatically slow ibogaine metabolism and increase both the intensity and duration of effects, raising cardiac and neurological risk. Leading clinics now include CYP2D6 genotyping in their pre-treatment screening.
What Professional Clinics Do for Medication Safety
Reputable ibogaine providers have developed rigorous protocols for patients co-prescribed antidepressants and opioids — a common clinical scenario. Their medical teams:
- Conducts comprehensive medication review during initial screening, identifying all potential interactions
- Creates individualized taper schedules supervised by physicians experienced in both psychiatric medication discontinuation and ibogaine pharmacology
- Monitors patients throughout the taper and washout period for discontinuation symptoms
- Verifies medication clearance through drug testing before proceeding with ibogaine treatment
- Has published clinical protocols for safely bridging from SSRI and SNRI regimens to ibogaine treatment
Co-Occurring Substance Issues
Many opioid-dependent patients also use kratom, either as a self-medication attempt or during failed tapering efforts. Kratom has its own opioid receptor activity and must be discontinued before ibogaine treatment.
Learn about ibogaine for kratom addictionSafety Protocols and Contraindications
Ibogaine is a powerful medicine with real medical risks. The difference between a safe, transformative treatment and a dangerous one lies entirely in the quality of medical screening, supervision, and emergency preparedness.
Required Medical Screening
No responsible clinic will administer ibogaine without completing all of the following:
12-Lead ECG
QTc interval measurement. Ibogaine can prolong QTc, and patients with existing QTc prolongation (>450ms for men, >470ms for women) or arrhythmias face elevated cardiac risk.
Comprehensive Blood Panel
Liver function (ALT, AST, bilirubin, albumin) — ibogaine is hepatically metabolized. Kidney function (creatinine, BUN, GFR). Electrolytes (potassium, magnesium, calcium) — imbalances increase cardiac risk.
Medication and Substance Review
Complete list of all current medications, supplements, and substances. Drug screening to verify current use patterns and identify undisclosed substances.
Cardiac History
Personal and family history of cardiac events, arrhythmias, sudden cardiac death, or cardiomyopathy. Echocardiogram may be required if history suggests structural abnormalities.
Psychological Assessment
Screening for active psychosis, schizophrenia, or severe psychiatric instability that could be exacerbated by the ibogaine experience.
Absolute Contraindications
Ibogaine should NOT be administered if any of the following are present:
- Prolonged QTc interval or history of cardiac arrhythmias
- Structural heart disease, heart failure, or cardiomyopathy
- Severe hepatic impairment (ibogaine is liver-metabolized)
- Severe renal impairment (impairs metabolite clearance)
- Active psychosis, schizophrenia, or schizoaffective disorder
- Current use of SSRIs, SNRIs, MAOIs, or other serotonergic medications (requires taper and washout first)
- Pregnancy or breastfeeding
- Uncontrolled seizure disorder
- Current use of medications that prolong QTc (certain antibiotics, antiarrhythmics, antipsychotics)
During Treatment: Medical Supervision
At properly equipped ibogaine clinics, the following monitoring is continuous throughout the ibogaine session:
- Continuous cardiac telemetry (real-time ECG monitoring)
- Pulse oximetry (blood oxygen saturation)
- Blood pressure monitoring at regular intervals
- Nursing assessment of consciousness, hydration, and comfort
- Emergency cardiac equipment (defibrillator, medications) on-site
- Physician on call or on-site throughout treatment
- IV access established for emergency medication administration
Opioid Addiction Is Not a Life Sentence
Whether you are struggling with prescription painkillers, heroin, fentanyl, or medication-assisted treatment you want to leave behind, ibogaine offers a path to genuine freedom. Not substitution. Not indefinite maintenance. Freedom.
Find a Verified Clinic
Browse vetted ibogaine providers with Total Alkaloid extract, comprehensive medical screening, cardiac monitoring, and integration support.
Safety & Screening
Understand the medical requirements, cardiac screening protocols, and contraindications before exploring treatment options.
Fentanyl-Specific Guide
Specialized protocols for fentanyl dependence, including stabilization, dosing adjustments, and extended monitoring for synthetic opioids.
Ibogaine is not FDA-approved and carries significant medical risks including cardiac complications. It requires comprehensive medical screening, continuous cardiac monitoring, and should only be administered in medically supervised clinical settings. The information on this page is educational and does not constitute medical advice. Always consult qualified healthcare providers before making treatment decisions.